What does TLRR stand for?

Target Lesion Response Rate (oncology)

This definition appears very rarely and is found in the following Acronym Finder categories:

Science, medicine, engineering, etc.

Other Resources:

<< Previous	Abbreviation Database Surfer		Next >>
Total Learning Research Institute (Virginia) Toxics Loading and Release Inventory (Chesapeake Bay Basin) Tongass Land and Resource Management Plan (US EPA) Technical Logistics Reference Network Time Lagged Recurrent Network Transport for London Road Network Tolerance Top-Level Requirement Overview Teaching and Learning Research Programme (UK) Track Last Reference Position		Terminal Landing System Timor-Leste Revenue Service Total Logistics Readiness and Sustainability Tramway and Light Railway Society (est. 1938) Transportable Laser Ranging System Total Logistics Readiness and Sustainability Analysis Twin Lakes Regional Sewer District (Monticello, IN) Transmission Low Range Sense Switch The Living Room Tour (Carole King music album) Trauma/Loss Response Team

Samples in periodicals archive:

As previously reported, in the Phase III clinical study, ABRAXANE demonstrated a superior response rate with an almost doubling of the reconciled target lesion response rate when compared with the solvent-based Taxol(R).

American Pharmaceutical Partners Announces Presentation of ...

ABRAXANE( )Clinical Trial Results In the pivotal Phase III clinical trial, ABRAXANE nearly doubled the overall target lesion response rate versus solvent-based paclitaxel (21.

Abraxis BioScience Launches ABRAXANE in Germany

ABRAXANE, consisting only of albumin-bound paclitaxel nanoparticles, is free of toxic solvents and demonstrated a superior response rate with an almost doubling of the reconciled target lesion response rate when compared with the solvent-based Taxol(R) in a prospectively randomized trial of 460 patients with metastatic breast cancer.

FDA Approves ABRAXANE(TM), First in New Class of Protein-Bound ...

This is now supported by the randomized Phase III trial in patients with metastatic breast cancer in which the target lesion response rate was higher with ABRAXANE as compared to TAXOL, and the time to tumor progression was longer in patients treated with ABRAXANE.

Positive ABRAXANE(TM) Phase III Trial in Metastatic Breast Cancer: ...

In that trial, ABRAXANE demonstrated a superior response rate with an almost doubling of the reconciled target lesion response rate when compared with Taxol([R]) in a prospectively randomized trial of 460 patients with metastatic breast cancer.

Abraxis BioScience and Biocon Limited Announce Approval of ABRAXANE ...

Data from the pivotal head-to-head trial results demonstrated that ABRAXANE nearly doubled the overall target lesion response rate versus Taxol(R) and achieved a 37 percent improvement in progression-free survival when compared to Taxol.

Abraxis BioScience Receives Approval in Canada for ABRAXANE to Treat ...